newsfilter
← Latest News
Business Wire·

Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab

Lenzilumab plus standard of care (SOC), resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels